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Mitochondria, the intracellular organelles responsible for energy production in eukaryotic cells, 
contain their own DNA (mtDNA). In animals, this DNA is the cell's only genetic material stored 
outside the nucleus, and replication of the mitochondrial genome is independent of the cell cycle and 
uses different enzymatic machinery. 
Human tumors frequently carry clonally expanded mutations in their mtDNA. Some of these 
mutations, which are the progeny of single mutated mtDNA molecules, may confer a neoplastic 
advantage on the host cell and contribute to cancer progression. The high prevalence of clonal 
mutations observed in tumor mtDNA has led to the assumption that the mitochondrial genome in 
cancer in genetically unstable. However, until now, the fidelity of genomic replication in the 
mitochondria of cancer cells had not been experimentally tested. 
Recently, Dr. Jason Bielas' lab in the Molecular Diagnostics Program of the Public Health Sciences 
Division was the first to measure the frequency of random single nucleotide substitutions in the 
mtDNA of cancerous and healthy tissue from 21 colorectal cancer patients using the highly sensitive 
Random Mutation Capture assay. Unlike clonal mutations, random mutations arise after a clonal 
population of cells has been established, and are only present in a subset of cells. 
The authors have previously demonstrated a >100 fold increase in the frequency of random 
mutations in the nuclear DNA of human tumors. However, surprisingly, they found that the frequency 
of mutations in mtDNA was decreased in colorectal cancer tumors relative to adjacent healthy tissue 
(Figure). 
In a series of subsequent experiments aimed at understanding the potential mechanisms involved, 
the authors demonstrated that the difference in mutation burden is attributable to a >3 fold reduction 
in C:G to T:A transitions in tumor tissue relative to normal colon. They also showed that tumor tissue 
is characterized by a shift in glucose metabolism from oxidative phosphorylation to anaerobic 
glycolysis – a process associated with decreased production of reactive oxygen species in the 
mitochondrial matrix.  Finally, they demonstrated that mutation frequency decreases concomitantly 
with reduced mitochondrial respiration in both normal and tumor tissue. This result is consistent with 
the hypothesis that a significant fraction of mtDNA mutagenesis occurs as a result of oxidative 
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damage, generated as a byproduct of oxidative phosphorylation. It also offers a plausible 
explanation for the lower frequency of random mutations in colonic tumor cells, particularly C:G to 
T:A transitions which are associated with oxidative damage. 
These findings suggest that, unlike with nuclear DNA, reduced mtDNA genetic diversity does not 
limit tumor progression; rather, normal mtDNA mutation rates may hinder cancer development. The 
results of this study therefore raise the possibility that cancer therapies focused on reactivating 
mitochondrial metabolism in order to increase mtDNA damage and mutation in tumor cells could 
potentially suppress malignant tumor growth. 
Ericson NG, Kulawiec M, Vermlust M, Sheahan K, O'Sullivan J, Salk JJ, Bielas JH. (2012). 
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